Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes. [PDF]
Front Endocrinol (Lausanne)Zhao W +6 more
europepmc +1 more source
Cytokines and drugs targeting cytokines in Graves' disease and thyroid eye disease. [PDF]
Front ImmunolFerrari SM +15 more
europepmc +1 more source
Severe nausea and vomiting after teprotumumab initiation with corticosteroid pretreatment: a case report. [PDF]
Int J OphthalmolYoun J, Firn K, Hawy E, Van Putten D.
europepmc +1 more source
Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema. [PDF]
AACE Endocrinol DiabetesLevy Barnett MJ +2 more
europepmc +1 more source
IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease. [PDF]
Sci RepKing DJ +19 more
europepmc +1 more source
Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease
Background: Thyroid eye disease (TED) is a condition caused by inflammatory damage to the periocular tissue that often leads to double vision. Teprotumumab is an insulin-like growth factor 1 receptor antibody that was FDA approved for the management of ...
Shwetha Mudalegundi; Peng Huang; Amanda D. Henderson; Andrew R. Carey
core
Diagnosis and treatment progress of upper eyelid abnormalities in thyroid-eye disease. [PDF]
Front Endocrinol (Lausanne)Gai C, Wang B.
europepmc +1 more source
Association Between Teprotumumab and Hearing Impairment: A Meta-Analysis. [PDF]
CureusBarnett MJ, deMelo M, Rego M, Casipit C.
europepmc +1 more source
Teprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations. [PDF]
Front Med (Lausanne)Wang Q +7 more
europepmc +1 more source
A Deep Learning Framework for Predicting Teprotumumab Treatment Response in Thyroid Eye Disease. [PDF]
Ophthalmol SciLangarica S +6 more
europepmc +1 more source